Business Wire

Nippon Gases Deploys Juniper Networks’ AI-Native Networking Platform to Foster Growth and Accelerate Innovation

12.12.2024 09:00:00 CET | Business Wire | Press release

Share

New wired and wireless network consolidates and transforms operations to underpin mission-critical gas production across Europe

Juniper Networks®, (NYSE: JNPR), a leader in secure, AI-Native Networking, today announced that Nippon Gases, one of the largest industrial gas companies in Europe, has implemented Juniper’s AI-Native wired and wireless LAN solutions to enhance mobile experiences across Nippon Gases’s IT and operational technology (OT) environments whilst streamlining network operations to foster digital innovation. As a key element of Juniper’s AI-Native Networking Platform, the new infrastructure uses Mist AI and cloud native capabilities to provide industry-leading efficiency, resiliency and visibility to Nippon Gases, resulting in exceptional user and operator experiences across offices, specialty labs, manufacturing plants, trucks, pipelines and ships.

With operations in 13 countries, Nippon Gases produces essential gases such as oxygen, nitrogen, hydrogen and carbon dioxide, serving multiple industries including healthcare, food and beverage, manufacturing and biotech.

By standardizing on Juniper’s unique AI for networking capabilities, Nippon Gases accelerates service deployment, simplifies operations, reduces total cost of ownership (TCO) and operational expenses, delivering exceptional end-to-end user and IT experiences. Additionally, Juniper’s AI-Native Networking Platform will help Nippon Gases accelerate new site set ups, increase trouble-ticket resolution with automation, optimize component inventory management and enable efficient, consistent network operations. The IT team can now automate the base configurations for each site and deploy the network rapidly with Zero Touch Provisioning. Role-based access delegates tasks to local teams while maintaining central control, simplifying maintenance through a standardized network. The IT team can put users’ digital experiences first and reduce the IT workload across the entire network life cycle.

News Highlights:

  • Juniper Mist Wireless (Wi-Fi) Assurance provides the fastest way to deploy and the easiest way to manage personalized Wi-Fi experiences, including up to 90 percent elimination in wireless trouble tickets, up to 85 percent fewer truck rolls and up to 9x faster deployment times in some instances. With Juniper, Nippon Gases’ Wi-Fi is fast, secure and reliable, even in the busiest, most experience-critical areas. For instance: reliable Wi-Fi supports seamless communication between industrial IoT devices, sensors and control systems, ensuring uninterrupted operations and real-time monitoring and enables technicians to access and update digital workflows or maintenance logs instantly.
  • Juniper Mist Wired Assurance delivers reliable, secure connectivity experiences for stationary devices and IoT endpoints through AI-driven network operations.
  • Juniper Networks® EX Series Switches enable unified visibility and control over both wireless and wired networking through a common Mist AI engine and microservices cloud infrastructure.
  • Juniper’s Marvis™ Virtual Network Assistant is used across Nippon Gases’ wired and wireless domains to simplify and automate network operations. Acting as an extended member of the IT team, Marvis provides proactive actions and Self-Driving Network™ operations. It continuously optimizes the user experience and provides visibility into impending problems. As a result, IT operations have clear and secure visibility into user and application experiences. AIOps boosts network reliability with automated actions, optimizing the network in real time and enabling rapid troubleshooting when needed.
  • A Juniper Enterprise Agreement (EA) gives Nippon Gases an easier way to purchase, consume and manage the portfolio of Juniper AI-Native Networking Platform software and support services anywhere in its business.

Supporting Quotes:

“Our business is incredibly dynamic and highly competitive. We are frequently building new factories, expanding our footprint and driving growth through acquisitions. These fast-paced changes mean IT typically has little lead time to support the new business demands that keep us ahead of the market. With Juniper’s AI-Native Networking Platform, we can rapidly yet easily deploy networks at new sites, ensuring seamless, secure connectivity and operational readiness. Juniper’s innovative solutions allow us to scale efficiently and consistently, meet business needs on tight timelines, and maintain the high standards our customers expect of a market leader.”

- Bjorn Dupont, IT Network Manager, Nippon Gases

“Nippon Gases needed to harmonize its complex network infrastructure to improve stability and support quality control. Centralized management was a particular challenge, as IT teams had to manage network devices individually across multiple countries. Simplifying network provisioning and operations therefore became a top priority. This requirement plays to our AI-Native Networking Platform’s strengths—offering insight-driven and automated solutions to mitigate manual, decentralized management. With Juniper, Nippon Gases can quickly identify, monitor and correlate network events in real time, proactively addressing potential issues before they impact operations and experiences.”

- Gos Hein van de Wouw, Vice President, Enterprise Sales, EMEA, Juniper Networks

About Juniper Networks

Juniper Networks believes that connectivity is not the same as experiencing a great connection. Juniper's AI-Native Networking Platform is built from the ground up to leverage AI to deliver the best and most secure user experiences from the edge to the data center and cloud. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn, and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212532821/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye